Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy

Due to the lack of efficient therapeutic options and clinical trial limitations, the FDA-approved drugs can be a good choice to handle Coronavirus disease (COVID-19). Many reports have enough evidence for the use of FDA-approved drugs which have inhibitory potential against target proteins of Severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shamsi, Anas, Mohammad, Taj, Anwar, Saleha, AlAjmi, Mohamed F., Hussain, Afzal, Rehman, Md. Tabish, Islam, Asimul, Hassan, Md. Imtaiyaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2020
Materias:
Bioinformatics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268261/
https://www.ncbi.nlm.nih.gov/pubmed/32441299
http://dx.doi.org/10.1042/BSR20201256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268261/
https://www.ncbi.nlm.nih.gov/pubmed/32441299
http://dx.doi.org/10.1042/BSR20201256

Ejemplares similares